Limited evidence exists regarding the long-term oncologic safety of biologic therapies, particularly IL-17 inhibitors and IL-23 inhibitors, in the management of psoriasis. This propensity score-matched retrospective cohort study assessed the risk of developing... ...

请注册登录后继续浏览